PL3206672T3 - Preparaty o przedłużonym uwalnianiu środków znieczulających miejscowo - Google Patents

Preparaty o przedłużonym uwalnianiu środków znieczulających miejscowo

Info

Publication number
PL3206672T3
PL3206672T3 PL16791778T PL16791778T PL3206672T3 PL 3206672 T3 PL3206672 T3 PL 3206672T3 PL 16791778 T PL16791778 T PL 16791778T PL 16791778 T PL16791778 T PL 16791778T PL 3206672 T3 PL3206672 T3 PL 3206672T3
Authority
PL
Poland
Prior art keywords
sustained
local anesthetics
release preparations
preparations
release
Prior art date
Application number
PL16791778T
Other languages
English (en)
Inventor
James A. Helliwell
Amanda MALONE
Rafi CHAPANIAN
Richard Liggins
Original Assignee
Eupraxia Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eupraxia Pharmaceuticals Inc. filed Critical Eupraxia Pharmaceuticals Inc.
Publication of PL3206672T3 publication Critical patent/PL3206672T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16791778T 2015-10-27 2016-10-27 Preparaty o przedłużonym uwalnianiu środków znieczulających miejscowo PL3206672T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562247159P 2015-10-27 2015-10-27
PCT/US2016/059141 WO2017075232A1 (en) 2015-10-27 2016-10-27 Sustained release formulations of local anesthetics
EP16791778.0A EP3206672B1 (en) 2015-10-27 2016-10-27 Sustained release formulations of local anesthetics

Publications (1)

Publication Number Publication Date
PL3206672T3 true PL3206672T3 (pl) 2018-09-28

Family

ID=57249923

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16791778T PL3206672T3 (pl) 2015-10-27 2016-10-27 Preparaty o przedłużonym uwalnianiu środków znieczulających miejscowo

Country Status (20)

Country Link
US (2) US11351124B2 (pl)
EP (1) EP3206672B1 (pl)
JP (1) JP2018531951A (pl)
KR (1) KR20180069055A (pl)
CN (1) CN108289857A (pl)
AU (1) AU2016343952A1 (pl)
BR (1) BR112018008415A2 (pl)
CA (1) CA3003159A1 (pl)
CL (1) CL2018001098A1 (pl)
DK (1) DK3206672T3 (pl)
ES (1) ES2672993T3 (pl)
IL (1) IL258852A (pl)
MX (1) MX2018005035A (pl)
PL (1) PL3206672T3 (pl)
PT (1) PT3206672T (pl)
RU (1) RU2018119121A (pl)
SG (1) SG11201803156TA (pl)
TR (1) TR201808237T4 (pl)
TW (1) TW201720427A (pl)
WO (1) WO2017075232A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
ES2672993T3 (es) * 2015-10-27 2018-06-19 Eupraxia Pharmaceuticals Inc. Formulaciones de liberación sostenida de anestésicos locales
AU2018345844B2 (en) 2017-10-06 2024-03-07 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
US12364792B2 (en) 2018-01-08 2025-07-22 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
AU2019270779B2 (en) 2018-05-12 2024-08-01 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
CN121426858A (zh) * 2019-04-10 2026-01-30 优普顺药物公司 制备期望的粒度分布和形态的药物晶体的方法

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2515898A (en) 1947-09-15 1950-07-18 Lilly Co Eli Procaine penicillin and therapeutic compositions
US2627491A (en) 1950-07-15 1953-02-03 Wyeth Corp Penicillin salts of substituted alkylene diamines
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
GB1523965A (en) 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE2805106A1 (de) * 1978-02-07 1979-08-16 Hoechst Ag Mikrokapseln aus polyvinylalkohol mit fluessigem, wasserunloeslichem fuellgut und verfahren zu deren herstellung
IT1205604B (it) 1981-06-23 1989-03-23 Pierrel Spa Procedimento per la eliminazione totale o parziale di acido aspartico e acido glutammico da idrolisati proteici e micele di amminoacidi con conseguete ottenimento di miscele di aminoacidi ad alto valore nutrizionale
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
GB2128984B (en) 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4888176A (en) 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
JPS61191609U (pl) 1985-05-20 1986-11-28
US5116870A (en) 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4940727A (en) 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
JPS63122620A (ja) 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US5310572A (en) 1987-02-03 1994-05-10 Dow Corning Corporation Process for forming a coated active agent-containing article
US5017716A (en) 1987-05-22 1991-05-21 E.R. Squibb & Sons, Inc. Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method
US4904646A (en) 1987-05-22 1990-02-27 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4906624A (en) 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4997837A (en) 1987-09-08 1991-03-05 Warner-Lambert Company 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4929620A (en) 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
US5001144A (en) 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4994494A (en) 1987-12-21 1991-02-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US5001128A (en) 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4900754A (en) 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US4939143A (en) 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4946864A (en) 1988-02-01 1990-08-07 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
DE68914495T2 (de) 1988-03-02 1994-10-27 Merck & Co Inc Antihypercholesterolemisches Mittel.
US5021453A (en) 1988-03-02 1991-06-04 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
US4920109A (en) 1988-04-18 1990-04-24 Merck & Co., Inc. Antifungal compositions and method of controlling mycotic infections
US5271946A (en) 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
MC2025A1 (fr) 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
US5166171A (en) 1988-05-13 1992-11-24 Hoechst Aktiengesellschaft 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiphenoxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, and in treating hypercholesterolemia
US4963538A (en) 1988-06-29 1990-10-16 Merck & Co., Inc. 5-oxygenated HMG-CoA reductase inhibitors
US4897402A (en) 1988-06-29 1990-01-30 Merck & Co., Inc. 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors
IT1226726B (it) 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5196440A (en) 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
DE3832570A1 (de) 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
US4906657A (en) 1988-12-21 1990-03-06 Warner-Lambert Company Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
US4957940A (en) 1988-12-21 1990-09-18 Warner-Lambert Company Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
US4950675A (en) 1988-12-21 1990-08-21 Warner-Lambert Company Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis
US4923861A (en) 1989-02-07 1990-05-08 Warner-Lambert Company 6-(2-(2-(Substituted amino)-3-quinolinyl) ethenyl and ethyl) tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5130306A (en) 1989-03-13 1992-07-14 Merck & Co., Inc. 5-Oxygenated HMG-COA reductase inhibitors
US5132312A (en) 1989-03-27 1992-07-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4970231A (en) 1989-06-09 1990-11-13 Merck & Co., Inc. 4-substituted HMG-CoA reductase inhibitors
US5102911A (en) 1989-06-09 1992-04-07 Merck & Co, Inc. 4-Substituted HMG-CoA reductase inhibitors
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US4992429A (en) 1989-08-24 1991-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel HMG-COA reductase inhibitors
US5098931A (en) 1989-08-31 1992-03-24 Merck & Co., Inc. 7-substituted HMG-CoA reductase inhibitors
US4946860A (en) 1989-11-03 1990-08-07 Rorer Pharmaceutical Corporation Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors
IT1237793B (it) 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5133947A (en) 1990-03-02 1992-07-28 Occidental Chemical Corporation Hydrous trivalent chromium oxide/carbon particles and method of making the same
US5025000A (en) 1990-03-02 1991-06-18 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitor compounds
US5084287A (en) 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5091185A (en) 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5112857A (en) 1990-09-04 1992-05-12 Merck & Co., Inc. Hmg-coa reductase inhibitor metabolites
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5182298A (en) 1991-03-18 1993-01-26 Merck & Co., Inc. Cholesterol lowering agents
US5654009A (en) 1991-03-25 1997-08-05 Fujisawa Pharmaceutical Co., Ltd. Delayed action preparation
US5256689A (en) 1991-05-10 1993-10-26 Merck & Co., Inc. Cholesterol lowering compounds
US5135935A (en) 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5250435A (en) 1991-06-04 1993-10-05 Merck & Co., Inc. Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
US5202327A (en) 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
WO1993004399A1 (en) * 1991-08-19 1993-03-04 Eastman Kodak Company Photographic paper with low oxygen permeability
EP0535937B2 (en) 1991-10-01 2008-05-21 Takeda Chemical Industries, Ltd. Prolonged release microparticle preparation and production of the same
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5260332A (en) 1992-02-07 1993-11-09 Merci & Co., Inc. Cholesterol lowering compounds
US5262435A (en) 1992-02-10 1993-11-16 Merck & Co., Inc. Cholesterol lowering compounds
US5286895A (en) 1992-02-19 1994-02-15 Merck & Co., Inc. Cholesterol lowering compounds
US5302604A (en) 1992-03-09 1994-04-12 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
US5369125A (en) 1992-07-17 1994-11-29 Merck & Co., Inc. Cholesterol-lowering agents
US5283256A (en) 1992-07-22 1994-02-01 Merck & Co., Inc. Cholesterol-lowering agents
JP3007687B2 (ja) 1992-09-10 2000-02-07 チルドレンズ メディカル センター コーポレイション 局所麻酔剤の持続性送達のための生分解性ポリマーマトリックス
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5317031A (en) 1992-10-19 1994-05-31 Merck & Co., Inc. Cholesterol lowering compounds
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
SE505146C2 (sv) 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
HUP9904065A3 (en) 1996-09-24 2001-10-29 Lilly Co Eli Coated particle formulations containing olanzapine
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
CA2407154A1 (en) 2000-04-27 2001-11-01 Verion, Inc Zero order release and temperature-controlled microcapsules and process for the preparation thereof
AU2001294458B2 (en) 2000-10-06 2004-03-11 Jagotec Ag Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight
AU2002232399A1 (en) 2000-11-03 2002-05-15 Control Delivery Systems Improved device and method for treating conditions of a joint
FR2816411B1 (fr) 2000-11-03 2003-07-04 Inst Nat Sante Rech Med Moyens de detection de la transformation pathologique de la proteine app et leurs applications
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20030152637A1 (en) 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
DE10140597A1 (de) * 2001-08-18 2003-03-06 Kuraray Specialities Europe Teilvernetzter Polyvinylalkohol
CA2510320C (en) 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
EP1583519A1 (en) 2002-12-20 2005-10-12 St. James Associates Llc/Faber Research Series High pressure compaction for pharmaceutical formulations
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20040191326A1 (en) 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US7063862B2 (en) 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
CA2533406C (en) 2003-07-31 2013-01-22 Sol-Gel Technologies Ltd. Microcapsules loaded with active ingredients and a method for their preparation
BRPI0414907A (pt) 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
RU2262355C1 (ru) 2004-02-09 2005-10-20 Уракова Наталья Александровна Способ лечения артрита методом внутрисуставной инъекции суспензии лекарственных средств
CN1679515A (zh) * 2004-04-06 2005-10-12 孙永海 镇痛药物缓释高分子微球及制备方法
US20090082321A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
PL2077830T3 (pl) 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
SE0700404L (sv) 2007-02-19 2008-08-20 Xylophane Ab Polymerfilm eller -beläggning innefattande hemicellulosa
US8962022B2 (en) 2007-03-27 2015-02-24 Aptalis Pharmatech, Inc. Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
CA2691597C (en) 2007-06-25 2016-04-05 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
US8846068B2 (en) 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
EP2321023B1 (en) 2008-07-18 2016-06-15 Prosonix Limited Process for improving crystallinity of fluticasone particles
WO2010017265A2 (en) 2008-08-07 2010-02-11 Calosyn Pharma Injectable extended release compositions and methods of treating arthritis using same
JP2010111592A (ja) 2008-11-04 2010-05-20 Aska Pharmaceutical Co Ltd プロピオン酸フルチカゾンを含む局所投与剤
US20110081420A1 (en) 2009-10-07 2011-04-07 Zyga Technology, Inc. Method of forming prolonged-release injectable steroids
CA2785468A1 (en) 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
KR101423237B1 (ko) 2010-05-04 2014-07-30 주식회사 삼양바이오팜 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
CN102070895B (zh) 2010-11-17 2013-03-27 无锡中科光远生物材料有限公司 一种核壳结构微胶囊及其制备方法
JP6083936B2 (ja) 2011-03-11 2017-02-22 大阪ガスケミカル株式会社 徐放性粒子の製造方法
BR112014010782A2 (pt) 2011-11-03 2017-06-13 Gtx Inc composições farmacêuticas de moduladores de receptor de androgênio seletivos e aplicações das mesmas
EP2819741B1 (en) 2012-02-27 2018-03-28 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
KR20150006869A (ko) 2012-05-03 2015-01-19 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
BR112015024234B1 (pt) 2013-03-21 2022-11-16 Eupraxia Pharmaceuticals USA LLC Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas
CA2960860A1 (en) 2014-09-19 2016-03-24 Eupraxia Pharmaceuticals Inc. Injectable microparticles for hyper-localized release of therapeutic agents
ES2672993T3 (es) * 2015-10-27 2018-06-19 Eupraxia Pharmaceuticals Inc. Formulaciones de liberación sostenida de anestésicos locales
WO2018026877A1 (en) 2016-08-05 2018-02-08 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds

Also Published As

Publication number Publication date
WO2017075232A1 (en) 2017-05-04
TR201808237T4 (tr) 2018-07-23
SG11201803156TA (en) 2018-05-30
CA3003159A1 (en) 2017-05-04
DK3206672T3 (en) 2018-06-18
CN108289857A (zh) 2018-07-17
ES2672993T3 (es) 2018-06-19
PT3206672T (pt) 2018-06-20
CL2018001098A1 (es) 2018-06-15
KR20180069055A (ko) 2018-06-22
US20180311173A1 (en) 2018-11-01
US12485097B2 (en) 2025-12-02
BR112018008415A2 (en) 2018-10-30
RU2018119121A3 (pl) 2020-03-10
EP3206672B1 (en) 2018-03-14
RU2018119121A (ru) 2019-11-28
IL258852A (en) 2018-06-28
EP3206672A1 (en) 2017-08-23
JP2018531951A (ja) 2018-11-01
AU2016343952A1 (en) 2018-05-10
TW201720427A (zh) 2017-06-16
US11351124B2 (en) 2022-06-07
MX2018005035A (es) 2018-09-06
US20230089355A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
IL282304A (en) Topical pharmaceutical compositions
IL281863A (en) Pharmaceutical compositions comprising meloxicam
DK3265421T3 (da) Doseringssystem
SI3529248T1 (sl) Farmacevtske spojine
EP3344318A4 (en) Patient interfaces
EP3291824C0 (en) ANTIMICROBIAL THERAPY
PL3368014T3 (pl) Nowe preparaty kannabinoidów
IL253719A0 (en) Pharmaceutical compositions for combination therapy
HUE058288T2 (hu) Pridopidin módosított hatóanyag-leadású készítményei
LT3298027T (lt) Antihelmintiniai depsipeptido junginiai
HUE053347T2 (hu) Glikopeptid-készítmények
DK3529240T3 (da) Farmaceutiske forbindelser
EP3424940A4 (en) Radiolabeled drug
PL3206672T3 (pl) Preparaty o przedłużonym uwalnianiu środków znieczulających miejscowo
EP3437644A4 (en) MEDICINE
DK3359555T3 (da) Doseringsplaner
HUE054351T2 (hu) Vegyületek
DK3256154T3 (da) Farmaceutisk formulering omfattende antistof
DK3597189T3 (da) Krystallinske forbindelser
KR20180084810A (ko) 정제 세트
EP3527216A4 (en) Medicine
DK3512518T3 (da) Buprenophinformuleringer med langvarig frigivelse
HUE054584T2 (hu) Maropitant készítmény
EP3334447A4 (en) CCK2R-drug conjugates
DK3728220T3 (da) Farmaceutiske forbindelser